Stock listing
LSE:0ABW Egetis Therapeutics AB Share Price
UK listing (LSE) of Egetis Therapeutics AB · home listing Stockholm:EGTX
Follow Egetis Therapeutics AB into a list and get an email when it puts out news.
Share price · LSE:0ABW
11.14 SEK +0.01 (+0.1%)
Close on Nov 20, 2026
- Day range
- 11.13 – 11.15 SEKNov 20, 2026
- Volume
- 255,262 sharesNov 20, 2026
- 52-week range
- 4.04 – 11.16 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 8.45M SEKMedian day 41,441 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:EGTX · Home | 11.12 SEK | -0.02 (-0.2%) | 1,812,099 | 11.12 | 11.14 | 11.12 | 11.14 | Close on Nov 20, 2026 |
| LSE:0ABW | 11.14 SEK | +0.01 (+0.1%) | 255,262 | 11.14 | 11.15 | 11.13 | 11.13 | Close on Nov 20, 2026 |
| Frankfurt:P0F | €0.96 EUR | -0.008 (-0.8%) | — | €0.964 | €0.964 | €0.96 | €0.968 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0ABW · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 11.14 | +0.02 | +0.2% | 11.12 | 11.14 | 11.11 | 136,747 | |
| 11.12 | +1.13 | +11.3% | 11.12 | 11.16 | 11.06 | 38,936,457 | |
| 9.99 | +0.29 | +3.0% | 9.99 | 9.99 | 9.99 | 2,985 | |
| 9.70 | -0.17 | -1.7% | 9.70 | 9.70 | 9.70 | 50,114 | |
| 9.87 | -0.73 | -6.9% | 9.82 | 10.06 | 9.82 | 74,919 | |
| 10.60 | 0.00 | 0.0% | 10.60 | 10.60 | 10.60 | 0 | |
| 10.60 | +0.44 | +4.3% | 10.46 | 10.78 | 10.46 | 351,875 | |
| 10.16 | +0.45 | +4.6% | 10.04 | 10.23 | 9.80 | 341,848 | |
| 9.71 | +0.43 | +4.6% | 9.60 | 9.71 | 9.445 | 22,171 | |
| 9.28 | +0.195 | +2.1% | 9.27 | 9.28 | 9.17 | 30,106 | |
| 9.085 | -0.265 | -2.8% | 9.14 | 9.14 | 9.085 | 1,829 | |
| 9.35 | +0.05 | +0.5% | 9.42 | 9.42 | 9.32 | 8,217 | |
| 9.30 | +0.17 | +1.9% | 9.20 | 9.30 | 9.155 | 39,680 | |
| 9.13 | +0.02 | +0.2% | 9.225 | 9.225 | 9.05 | 377,517 | |
| 9.11 | -0.285 | -3.0% | 9.24 | 9.24 | 9.03 | 174,242 | |
| 9.395 | +0.025 | +0.3% | 9.395 | 9.395 | 9.395 | 9,375 | |
| 9.37 | -0.155 | -1.6% | 9.345 | 9.37 | 9.33 | 187,930 | |
| 9.525 | -0.245 | -2.5% | 9.47 | 9.525 | 9.47 | 3,683 | |
| 9.77 | -0.16 | -1.6% | 9.77 | 9.77 | 9.77 | 6,048 | |
| 9.93 | +0.03 | +0.3% | 9.97 | 9.97 | 9.93 | 7,058 | |
| 9.90 | -0.12 | -1.2% | 9.85 | 9.90 | 9.84 | 19,251 | |
| 10.02 | +0.42 | +4.4% | 10.04 | 10.12 | 10.02 | 35,398 | |
| 9.60 | +0.04 | +0.4% | 9.33 | 9.62 | 9.31 | 23,854 | |
| 9.56 | +0.53 | +5.9% | 9.20 | 9.56 | 9.20 | 92,249 | |
| 9.03 | -0.49 | -5.1% | 9.12 | 9.21 | 9.03 | 79,350 | |
| 9.52 | +0.14 | +1.5% | 9.67 | 9.67 | 9.52 | 75,294 | |
| 9.38 | +0.41 | +4.6% | 9.19 | 9.38 | 9.08 | 81,946 | |
| 8.97 | +0.255 | +2.9% | 8.75 | 9.03 | 8.75 | 9,511 | |
| 8.715 | +1.065 | +13.9% | 8.61 | 9.065 | 8.375 | 380,552 | |
| 7.65 | -0.11 | -1.4% | 7.79 | 7.95 | 7.65 | 140,385 | |
| 7.76 | +0.01 | +0.1% | 7.745 | 7.945 | 7.69 | 648,299 | |
| 7.75 | +0.05 | +0.6% | 7.96 | 7.96 | 7.72 | 41,441 | |
| 7.70 | -0.15 | -1.9% | 7.80 | 7.80 | 7.70 | 143,636 | |
| 7.85 | +0.215 | +2.8% | 7.66 | 7.86 | 7.635 | 91,189 | |
| 7.635 | -0.595 | -7.2% | 7.89 | 7.89 | 7.635 | 14,350 | |
| 8.23 | +0.23 | +2.9% | 8.07 | 8.23 | 8.01 | 151,456 | |
| 8.00 | +0.20 | +2.6% | 8.01 | 8.01 | 7.95 | 107,595 | |
| 7.80 | -0.07 | -0.9% | 7.875 | 7.91 | 7.80 | 28,446 | |
| 7.87 | -0.105 | -1.3% | 7.925 | 8.12 | 7.87 | 179,347 | |
| 7.975 | -0.085 | -1.1% | 7.985 | 7.99 | 7.975 | 4,958 | |
| 8.06 | +0.01 | +0.1% | 8.00 | 8.06 | 8.00 | 185,181 | |
| 8.05 | +0.11 | +1.4% | 8.02 | 8.095 | 8.00 | 183,405 | |
| 7.94 | -0.01 | -0.1% | 8.00 | 8.015 | 7.88 | 180,260 | |
| 7.95 | +0.39 | +5.2% | 7.90 | 7.95 | 7.80 | 457,185 | |
| 7.56 | -0.16 | -2.1% | 7.71 | 7.91 | 7.56 | 20,500 | |
| 7.72 | -0.29 | -3.6% | 7.93 | 7.93 | 7.69 | 27,988 | |
| 8.01 | +0.01 | +0.1% | 7.93 | 8.02 | 7.93 | 11,811 | |
| 8.00 | +0.04 | +0.5% | 7.90 | 8.00 | 7.85 | 71,407 | |
| 7.96 | +0.03 | +0.4% | 7.85 | 7.96 | 7.772 | 87,806 | |
| 7.93 | -0.09 | -1.1% | 8.07 | 8.07 | 7.93 | 39,058 | |
| 8.02 | 0.00 | 0.0% | 8.04 | 8.04 | 8.02 | 40,175 | |
| 8.02 | -0.06 | -0.7% | 7.925 | 8.02 | 7.645 | 39,174 | |
| 8.08 | +0.475 | +6.2% | 8.065 | 8.08 | 8.04 | 21,590 | |
| 7.605 | +0.13 | +1.7% | 7.605 | 7.605 | 7.605 | 3,458 | |
| 7.475 | +0.40 | +5.7% | 7.475 | 7.475 | 7.475 | 6,876 | |
| 7.075 | +0.255 | +3.7% | 7.145 | 7.155 | 7.055 | 25,042 | |
| 6.82 | -0.24 | -3.4% | 7.01 | 7.01 | 6.79 | 48,043 |
- Ticker
- LSE:0ABW
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- LSE
- Currency
- SEK
What changed lately
Latest news release · Sep 29, 2026
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients with MCT8 Deficiency
Latest earnings call · Aug 21, 2026
Egetis Therapeutics (Stockholm:EGTX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 62 slides
Calls
Replays
Egetis Therapeutics (Stockholm:EGTX) Q2 2026 Earnings Call
Fri, Aug 21, 2026 · 8:00 AM ET
Watch TranscriptEgetis Therapeutics (Stockholm:EGTX) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 4:00 AM ET
Watch Transcript
Latest news
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients with MCT8 Deficiency
Sep 29, 2026
Closed 8.72 (+13.9%) on Sep 29, 2026
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
Sep 28, 2026
Closed 8.72 (+13.9%) on Sep 29, 2026
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
Sep 3, 2026
Closed 8.01 (+0.1%) on Sep 3, 2026
Egetis' Interim report Q2 2026
Aug 21, 2026
Closed 7.08 (+3.7%) on Aug 21, 2026
Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026
Aug 7, 2026
Closed 6.98 (+2.3%) on Aug 10, 2026
Change in the number of shares and votes in Egetis Therapeutics
May 29, 2026
Closed 5.97 (0.0%) on May 29, 2026
Exercise of options under employee stock option program and notification of insider trading
May 13, 2026
Closed 6.83 (+2.2%) on May 13, 2026
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.
May 5, 2026
Closed 6.54 (+10.7%) on May 5, 2026
Interim ReportQ12026
May 3, 2026
Closed 5.91 (+5.3%) on May 4, 2026
Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026
Apr 24, 2026
Closed 5.84 (-2.3%) on Apr 24, 2026
Financings
Private placement of new ordinary shares
Apr 21, 2026 · US$38.2M
Closed: SEK 350M raised · SEK 5.25 a share · Stifel +2
Dealers: Stifel (lead), Van Lanschot Kempen (co-lead), DNB Carnegie (co-lead)
Buyers: Frazier Life Sciences (expected to anchor the Directed Issue); Invus; Woodline Partners; Parkman Healthcare Partners; Linc AB; The Fourth Swedish National Pension Fund; Cidro Förvaltning AB (Peter Lindell); Unionen
Use of proceeds: Preparing Emcitate U.S. commercialization, RTH-beta indication expansion, working capital and general corporate purposes
Decks
Investor Presentation (October 2026)
Investor deck · 62 slides · October 2026
Q2 2026 Earnings Presentation
Earnings · 13 slides · Aug 21, 2026
Investor Presentation (August 2026)
Investor deck · 102 slides · August 2026
Investor Presentation (March 2026)
Investor deck · 101 slides · March 2026
Egetis Therapeutics AB on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 18 in the last 12 months · 18 in all · newest Sep 29, 2026 · oldest 2026
- Calls
- 2 calls with a replay · 2 with a transcript · latest Aug 21, 2026
- Decks
- 37 decks · latest October 2026
Where Egetis Therapeutics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:EGTX · Home listing | Stockholm | Sweden | SEK |
| LSE:0ABW · This page | LSE | United Kingdom | SEK |
| OTC:PDPHF | OTC | United States | USD |
| Lang & Schwarz:A1JH3B | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1JH3B | LS Exchange | Germany | EUR |
| Frankfurt:P0F | Frankfurt | Germany | EUR |
| Aquis:EGTXS | Aquis | United Kingdom | SEK |
| gettex:P0F | gettex | Germany | EUR |
| Aquis:EGTXS | Aquis | United Kingdom | SEK |
| Munich:P0F | Munich | Germany | EUR |
| Stuttgart:P0F | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Egetis Therapeutics AB.